𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Erratum to: A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis

✍ Scribed by Kiwamu Okita; Isao Sakaida; Mitsuru Okada; Akira Kaneko; Kazuaki Chayama; Michio Kato; Michio Sata; Harumasa Yoshihara; Noriyuki Ono; Yoshikazu Murawaki

Publisher
Springer Japan
Year
2010
Tongue
English
Weight
75 KB
Volume
45
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open-label flexible-dose pilot study to
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
✍ Joseph H. Friedman; Robert M. Berman; Christopher G. Goetz; Stewart A. Factor; W 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

## Abstract Psychosis affects at least 5% to 8% of medication‐treated patients with idiopathic Parkinson's disease (PD). Treatment options include reducing medications used for the treatment of PD‐related motor symptoms or introducing an atypical antipsychotic drug. Only clozapine has been demonstr

A multicentre, randomized, double-blind,
A multicentre, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate Alzheimer's disease: the MALT study
✍ Bruno Dubois; Ian McKeith; Jean-Marc Orgogozo; Owen Collins; Didier Meulien 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB 👁 3 views

Background. Metrifonate is a long-lasting acetylcholinesterase inhibitor being developed for the symptomatic treatment of Alzheimer's disease (AD). Objectives. This study compared the ecacy, tolerability and safety of two doses of metrifonate in patients with mild-to-moderate AD, over a 26-week tre